ER-Positive, HER2-Negative Metastatic Breast Cancer

In this segment, Dr. Gregory Vidal explains how biomarker test results directly influence treatment decisions in ER-positive, HER2-negative metastatic breast cancer.

In this segment, Dr. Gregory Vidal outlines what a typical first-line treatment plan looks like for patients with ER-positive, HER2-negative metastatic breast cancer.

In this segment, Dr. Gregory Vidal explains how hormone, or endocrine, therapies work to slow or stop cancer growth in ER-positive, HER2-negative metastatic breast cancer.

In this segment, Dr. Gregory Vidal explains why CDK4/6 inhibitors are commonly added to endocrine therapy in the treatment of ER-positive, HER2-negative metastatic breast cancer.

In this segment, Dr. Gregory Vidal discusses how initial treatment options are selected for patients with ER-positive, HER2-negative metastatic breast cancer and highlights the importance of individualized care.

In this segment, Dr. Gregory Vidal discusses practical steps patients can take to manage side effects while undergoing treatment for ER-positive, HER2-negative metastatic breast cancer.

In this segment, Dr. Gregory Vidal explains what it means when endocrine therapy stops working in ER-positive, HER2-negative metastatic breast cancer and why resistance can develop over time.

In this segment, Dr. Gregory Vidal discusses the role of estrogen receptor antagonists in the treatment of ER-positive, HER2-negative metastatic breast cancer following progression on prior endocrine therapy.

In this closing segment, Dr. Gregory Vidal discusses the importance of patient engagement and empowerment throughout the course of ER-positive, HER2-negative metastatic breast cancer.